Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer
Phase Ib (China only):
Approximately 15 patients
Phase Ⅱ (globally):
Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US
only)